Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) Short Interest Update

Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) was the recipient of a significant decrease in short interest during the month of April. As of April 15th, there was short interest totaling 16,112 shares, a decrease of 58.7% from the March 31st total of 38,967 shares. Based on an average daily trading volume, of 30,779 shares, the days-to-cover ratio is presently 0.5 days. Approximately 1.2% of the shares of the company are short sold.

Hedge Funds Weigh In On Sonoma Pharmaceuticals

An institutional investor recently raised its position in Sonoma Pharmaceuticals stock. DRW Securities LLC increased its holdings in Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) by 257.2% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 60,977 shares of the company’s stock after purchasing an additional 43,907 shares during the quarter. DRW Securities LLC owned 3.59% of Sonoma Pharmaceuticals worth $222,000 at the end of the most recent reporting period. 1.95% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Sonoma Pharmaceuticals in a research note on Monday, December 29th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company has a consensus rating of “Sell”.

Sonoma Pharmaceuticals Price Performance

Shares of SNOA opened at $1.14 on Monday. Sonoma Pharmaceuticals has a 52 week low of $0.85 and a 52 week high of $6.92. The company has a market capitalization of $1.97 million, a price-to-earnings ratio of -0.56 and a beta of 1.76. The stock’s 50-day moving average price is $2.44 and its 200-day moving average price is $3.14.

Sonoma Pharmaceuticals (NASDAQ:SNOA) last issued its earnings results on Tuesday, February 10th. The company reported ($0.35) EPS for the quarter, missing analysts’ consensus estimates of ($0.29) by ($0.06). Sonoma Pharmaceuticals had a negative return on equity of 42.56% and a negative net margin of 19.04%.The company had revenue of $4.35 million during the quarter, compared to analysts’ expectations of $5.47 million.

Sonoma Pharmaceuticals Company Profile

Sonoma Pharmaceuticals, Inc is a specialty dermatology company focused on developing and commercializing topical prescription and over-the-counter products for inflammatory and infectious skin conditions. Publicly traded on Nasdaq under the symbol SNOA, the company concentrates its efforts on areas such as acne, rosacea, dermatitis and wound care, aiming to provide physicians and patients with innovative treatment options.

At the heart of Sonoma’s technology platform lies its proprietary Triphasic drug delivery system, which enables the timed release of active ingredients through three distinct gel phases.